NASDAQ:NBIX - Neurocrine Biosciences Stock Price, Forecast & News

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings data on Monday, November, 4th. The company reported $0.56 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.63 by $0.07. The firm earned $222.09 million during the quarter, compared to analyst estimates of $211.31 million. Neurocrine Biosciences had a net margin of 3.12% and a return on equity of 5.67%. The firm's revenue for the quarter was up 46.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.52 earnings per share. View Neurocrine Biosciences' Earnings History.

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Neurocrine Biosciences.

Neurocrine Biosciences will be holding an earnings conference call on Tuesday, February 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

15 analysts have issued 12 month target prices for Neurocrine Biosciences' stock. Their forecasts range from $88.00 to $153.00. On average, they expect Neurocrine Biosciences' stock price to reach $116.33 in the next twelve months. This suggests a possible upside of 13.9% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.

Media headlines about NBIX stock have been trending negative this week, InfoTrie reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neurocrine Biosciences earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Neurocrine Biosciences.

Neurocrine Biosciences saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 4,240,000 shares, a decrease of 8.4% from the December 15th total of 4,630,000 shares. Based on an average trading volume of 906,500 shares, the days-to-cover ratio is currently 4.7 days. Currently, 4.7% of the company's stock are short sold. View Neurocrine Biosciences' Current Options Chain.

Some companies that are related to Neurocrine Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), AbbVie (ABBV), Gilead Sciences (GILD), Twilio (TWLO), Exelixis (EXEL), Illumina (ILMN) and salesforce.com (CRM).

Neurocrine Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Mckinley Capital Management LLC Delaware (0.18%), Rhenman & Partners Asset Management AB (0.13%), Campbell & CO Investment Adviser LLC (0.03%), Nisa Investment Advisors LLC (0.02%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%) and Mission Wealth Management LP (0.02%). Company insiders that own Neurocrine Biosciences stock include Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

NBIX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Tocqueville Asset Management L.P., Mainstay Capital Management LLC ADV and Janney Montgomery Scott LLC. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith and Matt Abernethy. View Insider Buying and Selling for Neurocrine Biosciences.

NBIX stock was purchased by a variety of institutional investors in the last quarter, including Mckinley Capital Management LLC Delaware, Campbell & CO Investment Adviser LLC, Nisa Investment Advisors LLC, Zurcher Kantonalbank Zurich Cantonalbank , DNB Asset Management AS, Red Spruce Capital LLC, IFM Investors Pty Ltd and Mission Wealth Management LP. View Insider Buying and Selling for Neurocrine Biosciences.

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NBIX stock can currently be purchased for approximately $102.18.

Neurocrine Biosciences has a market capitalization of $9.41 billion and generates $451.24 million in revenue each year. The company earns $21.11 million in net income (profit) each year or $0.22 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe.View Additional Information About Neurocrine Biosciences.

The official website for Neurocrine Biosciences is http://www.neurocrine.com/.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]